Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.

Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
Tools for Experimental
and Clinical
Immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in Cancer and
Autoimmune Diseases

Treat

Clinical Trials
to test CAR-T
and Bispecific
Antibody Strategies

Teach

Advancing
Education
and Training in
Immunotherapies

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies

Jérôme Avouac 1, Maurine Jouret 2, Samuel Bitoun 3, Raphaël Borie 4, Divi Cornec 5, Valérie Devauchelle-Pensec 5, Philippe Dieude 6, Bruno Fautrel 7, Jacques-Eric Gottenberg 8, Pierre-Antoine Juge 6, Jean Guillaume Letarouilly 9, Sophie Hecquet 10, Yves-Marie Pers 11, Christophe Richez 12, Adeline Ruyssen-Witrand 13, Adrien Schvartz 14, Raphaèle Seror 3, Marc Scherlinger 8; Club for Innovative Immunotherapies in Immune-mediated Inflammatory Diseases

Lancet Rheumatol . | 2026 Nov;8(11):e908-e920. doi: 10.1016/S2665-9913(26)00184-0.

Time for a disease-specific approach to lymphoma in Sjögren disease

Gaetane Nocturne & Marguerite Vignon

Nature Reviews Rheumatology (2026) | Nocturne, G., Vignon, M. Time for a disease-specific approach to lymphoma in Sjögren disease. Nat Rev Rheumatol (2026). https://doi.org/10.1038/s41584-026-01425-y DOI https://doi.org/10.1038/s41584-026-01425-y

See all Publications